false 0001826457 0001826457 2024-05-28 2024-05-28

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 28, 2024

 

 

MONTE ROSA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-40522   84-3766197

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

321 Harrison Avenue, Suite 900

Boston, MA 02118

(Address of principal executive offices, including zip code)

(617) 949-2643

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share   GLUE   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 28, 2024, the Compensation, Nomination and Corporate Governance Committee of Board of Directors of Monte Rosa Therapeutics, Inc. (the “Company”) promoted Jennifer Champoux, the Company’s Chief People and Operations Officer, to serve as the Company’s Chief Operating Officer, effective as of May 28, 2024 (the “Effective Date”).

Ms. Champoux, age 52, has served as the Company’s Chief People and Operations Officer since March 2023, and was previously the Company’s Senior Vice President of Operations from March 2021 to March 2023. Prior to joining the Company, from June 2017 to March 2021, Ms. Champoux was with H3 Biomedicine Inc., leading operations, communications, and finance operations teams. Earlier, Ms. Champoux was with Novartis Institutes from Biomedical Research, leading operations for the Discovery Chemistry group in Cambridge. She previously worked in various roles at Merck and Array BioPharma. Ms. Champoux holds an M.S. in chemistry from Indiana University and brings over 15 years of diverse operations experience, including site operations, strategic planning, finance, communications, and culture and employee engagement.

There are no arrangements or understandings between Ms. Champoux or any other person pursuant to which Ms. Champoux was promoted. There are no family relationships between Ms. Champoux and any other director, executive officer or nominees thereof of the Company. There are no related party transactions between the Company and Ms. Champoux that would require disclosure under Item 404(a) of Regulation S-K under the Exchange Act.

Item 7.01. Regulation FD Disclosure.

On May 30, 2024, the Company issued a press release announcing Ms. Champoux’s promotion and the promotions of two other individuals. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such filing. The Company undertakes no obligation to update, supplement or amend the material attached hereto as Exhibit 99.1.

 

Item 9.01.

Financial Statements and Exhibits

(d) Exhibits

 

99.1    Press Release issued by Monte Rosa Therapeutics, Inc. dated May 30, 2024.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Monte Rosa Therapeutics, Inc.
Date: May 30, 2024     By:  

/s/ Markus Warmuth

      Markus Warmuth
      President and Chief Executive Officer

Exhibit 99.1

 

LOGO

Monte Rosa Therapeutics Announces Leadership Team Promotions

BOSTON, Mass., May 30, 2024 – Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced three leadership team promotions effective immediately: Sharon Townson, Ph.D., to Chief Scientific Officer; Phil Nickson, Ph.D., J.D., to Chief Business and Legal Officer; and Jennifer Champoux to Chief Operating Officer.

“I am very pleased to announce the well-deserved promotions of Sharon, Phil and Jennifer to expanded roles on our leadership team,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics. “Each has played a critical role in advancing our pipeline programs, enhancing our QuEEN™ drug discovery engine, developing relationships with premier biopharma companies, and building an outstanding organization. I look forward to continued work and collaboration with this talented group as we advance our pipeline programs targeting cancers and immune-related diseases and further leverage the potential of our AI/ML-driven discovery engine.”

Sharon Townson, Ph.D., promoted to Chief Scientific Officer, joined Monte Rosa as Chief Technology Officer and brings expertise in molecular glues and targeted protein degradation technology platforms. She joined the Company from Kymera Therapeutics, where she served as Executive Director of Platform Biology. Previously, she was on the leadership team of Warp Drive Bio and was responsible for developing their novel molecular glue approach to target KRAS. Sharon began her career at Pfizer as a structural biologist and holds a Ph.D. in structural biology and biochemistry from the University of Manchester Institute of Technology.

Phil Nickson, Ph.D., J.D., promoted to Chief Business and Legal Officer, joined the Company as General Counsel and has provided general legal support, including work on intellectual property matters and external business transactions. Phil joined Monte Rosa with over 15 years of life sciences legal experience. Previously, he was with Momenta Pharmaceuticals for over 10 years, through the company’s acquisition by Johnson and Johnson. Phil began his legal career with Fish and Richardson in Boston. He holds a J.D. from Suffolk University and a Ph.D. from the University of Manchester.

Jennifer Champoux, promoted to Chief Operating Officer, joined Monte Rosa as Vice President of Operations, leading overall corporate operations and Human Resources. Jen brings over 15 years of diverse operations experience, including site operations, strategic planning, finance, communications, and culture and employee engagement. Previously, she was with H3 Biomedicine, leading operations, communications, and finance operations teams. Earlier, Jen was with Novartis Institutes for Biomedical Research, leading operations for the Discovery Chemistry group in Cambridge. She previously worked in various roles at Merck and Array BioPharma. Jen holds an M.S. in chemistry from Indiana University.

About Monte Rosa

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided

LOGO

 

chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond, and has a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit www.monterosatx.com.

Investors

Andrew Funderburk

ir@monterosatx.com

Media

Cory Tromblee, Scient PR

media@monterosatx.com

###

v3.24.1.1.u2
Document and Entity Information
May 28, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001826457
Document Type 8-K
Document Period End Date May 28, 2024
Entity Registrant Name MONTE ROSA THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-40522
Entity Tax Identification Number 84-3766197
Entity Address, Address Line One 321 Harrison Avenue
Entity Address, Address Line Two Suite 900
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02118
City Area Code (617)
Local Phone Number 949-2643
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value per share
Trading Symbol GLUE
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Monte Rosa Therapeutics (NASDAQ:GLUE)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Monte Rosa Therapeutics Charts.
Monte Rosa Therapeutics (NASDAQ:GLUE)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Monte Rosa Therapeutics Charts.